Genfit SA (FR:GNFT)
:GNFT
Top Page
Genfit
(GNFT)
Select Model
Select Model
Rating:45Neutral
Price Target:
€8.00
▼(-7.83% Downside)
Action:ReiteratedDate:04/10/26
The score is held down primarily by weak financial performance—renewed losses, negative free cash flow, and a stressed balance sheet with negative equity. Technicals are mixed (better vs. longer-term averages but muted momentum), while valuation is constrained by losses and the absence of a dividend.
Positive Factors
Diversified revenue model: diagnostics plus partnerships
A mixed model of product commercialization plus licensing/collaboration revenues provides durable, multi-channel cash generation potential. Product sales can create recurring revenue while partnerships offer upfront, milestone and royalty streams that reduce reliance on a single source over the medium term.
Negative Factors
Negative shareholders' equity and weakened capitalization
Negative equity indicates accumulated losses have eroded the capital base, reducing financial flexibility and increasing refinancing risk. This structural weakness constrains investment capacity, may impair partner confidence, and elevates the importance of external funding or turnaround in profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified revenue model: diagnostics plus partnerships
A mixed model of product commercialization plus licensing/collaboration revenues provides durable, multi-channel cash generation potential. Product sales can create recurring revenue while partnerships offer upfront, milestone and royalty streams that reduce reliance on a single source over the medium term.
Read all positive factors
Genfit (GNFT) vs. iShares MSCI France ETF (EWQ)
Market Cap
€432.95M
Dividend YieldN/A
Average Volume (3M)245.75K
Price to Earnings (P/E)―
Beta (1Y)1.41
Revenue Growth-45.41%
EPS Growth-273.69%
CountryFR
Employees180
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.03
Shares Outstanding50,080,223
10 Day Avg. Volume239,968
30 Day Avg. Volume245,745
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-11.11
Price to Sales (P/S)4.01
P/FCF Ratio-9.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€15.00Price Target Upside72.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.19
Revenue Forecast (FY)€81.08M
Genfit Business Overview & Revenue Model
Company Description
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients wi...
How the Company Makes Money
Genfit’s revenue model is primarily tied to (1) commercialization and sales of diagnostic products and related services, and (2) partnering activities typical of biopharmaceutical companies, such as licensing agreements and collaboration arrangeme...
Genfit Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
28
Negative
Cash Flow
35
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 65.43M | 67.00M | 28.57M | 20.20M | 80.07M |
| Gross Profit | 14.55M | 66.70M | 28.22M | 19.95M | 79.91M |
| EBITDA | -8.04M | 8.35M | -22.24M | -23.60M | 71.89M |
| Net Income | -85.97M | 1.51M | -28.89M | -23.72M | 67.26M |
Balance Sheet | |||||
| Total Assets | 157.93M | 151.42M | 173.87M | 215.54M | 281.72M |
| Cash, Cash Equivalents and Short-Term Investments | 101.09M | 81.79M | 77.79M | 140.55M | 258.76M |
| Total Debt | 150.69M | 62.13M | 70.18M | 75.28M | 74.23M |
| Total Liabilities | 181.58M | 82.20M | 105.92M | 121.01M | 162.62M |
| Stockholders Equity | -23.64M | 69.22M | 67.95M | 94.53M | 119.10M |
Cash Flow | |||||
| Free Cash Flow | -26.71M | 14.22M | -57.92M | -72.64M | 99.38M |
| Operating Cash Flow | -25.32M | 15.20M | -55.43M | -72.64M | 99.92M |
| Investing Cash Flow | -3.63M | -1.04M | 2.23M | -46.27M | -3.38M |
| Financing Cash Flow | 48.07M | -10.57M | -5.10M | -3.79M | -8.92M |
Genfit Technical Analysis
Positive
8.68
Price Trends
8.02
Positive
6.47
Positive
4.98
Positive
Market Momentum
0.01
Positive
54.56
Neutral
63.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:GNFT, the sentiment is Positive. The current price of 8.68 is above the 20-day moving average (MA) of 8.51, above the 50-day MA of 8.02, and above the 200-day MA of 4.98, indicating a bullish trend. The MACD of 0.01 indicates Positive momentum. The RSI at 54.56 is Neutral, neither overbought nor oversold. The STOCH value of 63.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:GNFT.
Genfit Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | €24.40M | -1.75 | ― | ― | ― | ― | |
46 Neutral | €8.56B | -24.91 | ― | ― | ― | 18.52% | |
46 Neutral | €939.49M | -2.08 | ― | ― | -12.84% | -81.94% | |
46 Neutral | €14.02M | -2.41 | ― | ― | ― | ― | |
45 Neutral | €432.95M | -0.86 | -63.70% | ― | -45.41% | -273.69% | |
45 Neutral | €106.92M | -1.26 | ― | ― | 52.55% | -5.97% |
* Healthcare Sector Average
FR:GNFT
Genfit
8.68
5.57
179.28%
FR:ABVX
Abivax SA
107.90
102.54
1913.06%
FR:IVA
Inventiva
4.53
1.69
59.61%
FR:POXEL
Poxel SA
0.26
-0.20
-43.26%
FR:ALVAL
Valbiotis SA
1.03
0.02
1.68%
FR:MAAT
MaaT Pharma
5.68
-0.22
-3.73%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.